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Abstract
Purpose Within the last decade, SurePath and ThinPrep
[both liquid-based cytology (LBC) tests] have replaced
conventional cytology (CC) as primary test method in
cervical cancer screening programs of multiple countries.
The aim of our study was to examine the effect in the
Dutch screening program.
Methods All primary smears taken within this program
from 2000 to 2011 were analyzed using the nationwide
registry of histo- and cytopathology (PALGA) with a fol-
low-up until March 2013. The percentage of smears clas-
sified as borderline/mildly dyskaryotic (BMD) and[BMD
as well as CIN and cervical cancer detection rates were
compared between SurePath and ThinPrep versus CC by
logistic regression analyses (adjusted for age, screen
region, socioeconomic status, and calendar time).
Results We included 3,118,685 CC, 1,313,731 SurePath,
and 1,584,587 ThinPrep smears. Using SurePath resulted in
an increased rate of primary smears classified as[BMD
[odds ratio (OR) = 1.12 (95% confidence interval (CI)
1.09–1.16)]. CIN I and II? detection rates increased by 14
% [OR = 1.14 (95% CI 1.08–1.20)] and 8 % [OR = 1.08
(95% CI 1.05–1.12)]. Cervical cancer detection rates were
unaffected. Implementing ThinPrep did not result in major
alterations of the cytological classification of smears, and it
did not affect CIN detection rates. While not significant,
cervical cancer detection rates were lower [OR = 0.87
(95% CI 0.75–1.01)].
Conclusions The impact of replacing CC by LBC as
primary test method depends on the type of LBC test used.
Only the use of SurePath was associated with increased
CIN II? detection, although it simultaneously increased the
detection of CIN I.
Keywords Cervical intraepithelial neoplasia 
Liquid-based cytology  SurePath  ThinPrep 
Conventional cytology  Screening
Introduction
Since the 1980s, a national cervical cancer screening pro-
gram exists in the Netherlands. From 1996 onwards,
women are invited every five years from ages 30 to
60 years. The screening strategy consists of primary
cytology screening with triage by repeat cytology or triage
by a combination of repeat cytology and human papillo-
mavirus (HPV) testing (Fig. 1). Despite its limited sensi-
tivity [1], the conventional cytology test has long been used
as primary test method.
Within the last 10–15 years, conventional cytology has
been replaced by liquid-based cytology (LBC) tests Sur-
ePath or ThinPrep in most of Dutch laboratories processing
primary screening tests. Conventional cytology and both
LBC systems share the same method of sampling cells
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from the cervix (i.e., scraping off cells with a brush or
similar device from the histological transition zone). LBC
differs from conventional cytology with respect to the
transfer of cells from brush to slide: With conventional
cytology, cells are directly smeared on a slide, while with
LBC, the brush is first rinsed into a vial with a preservative
fluid and then transported to a laboratory [2]. In the labo-
ratory, an uniform layer of cells is prepared on the slide [3,
4]. It is thought that this method of cell transfer (which
differs between SurePath and ThinPrep) results in a better
representation of the entire sample as compared to con-
ventional cytology [5]. A review which evaluated the
applicability of LBC in the Dutch cervical cancer screening
program concluded that further research was needed to
determine the applicability of SurePath. Furthermore, they
recommended to further analyze the costs and benefits of
ThinPrep before deciding whether or not to implement this
method [6]. Yet, public health authorities in the Nether-
lands permitted use of both LBC systems based on per-
ceived advantages such as: ease of processing, reduction in
unsatisfactory slides [7–10], and time needed to read the
slides [10–13]. Finally, the use of LBC allowed for easier
application of HPV co-testing [14, 15].
The use of conventional cytology as primary test method
has also been replaced by the use of SurePath and/or
ThinPrep in many other countries with and without orga-
nized cervical cancer screening programs, such as
Denmark, the UK, and the USA [16, 17]. It is believed that
the sensitivity of LBC for detecting cervical intraepithelial
neoplasia (CIN) II? lesions is similar to that of conven-
tional cytology [18, 19]. However, when stratifying for the
type of LBC test used, many studies have been published
comparing CIN detection between ThinPrep and conven-
tional cytology [2, 5, 11, 20–22], while only two studies
have compared CIN detection between SurePath and con-
ventional cytology [10, 23]. Moreover, no studies have
been published comparing CIN detection rates between the
three types of cytology tests. As the outcome of all cervix
uteri cytological and histological tests taken within the
Dutch screening program were available (i.e., are regis-
tered in the Dutch Pathology Register (i.e., in PALGA)
[24]) and we were able to deduce which type of primary
cytology test had been used, we assessed whether differ-
ences in CIN detection rates were present when screened
by SurePath or ThinPrep as compared to conventional
cytology. In addition, we assessed the effect on cervical
cancer detection rates and on the classification of smears.
Methods
Information on all cervix uteri cytological and histological
tests in the Netherlands registered from January 2000 until
March 2013 was retrieved from PALGA. Women are
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Fig. 1 Triage protocol consisting of triage cytology without HPV testing (a) and with HPV testing (b). HPV human papillomavirus, BMD
borderline and mildly dyskaryotic smears
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identified through their birth date and the first eight letters
of their (maiden) family name. This identification code
enables linkage of tests belonging to the same woman,
allowing us to follow individual screening histories. We
identified primary smears (i.e., first smear of an episode)
taken within the national cervical cancer screening pro-
gram between January 2000 and December 2011. A min-
imum duration of 15-month follow-up was ensured as data
until March 2013 were available. Histologically confirmed
CIN lesions and cervical cancer cases were identified by
selecting all PALGA records that included corresponding
pathology codes. Detection of these conditions was
assigned to the type of cytology test used. Age was defined
as the woman’s age at the time of the primary smear and
was categorized as 29–33, 34–38, 39–43, 44–48, 49–53,
54–58, and 59–63 years. As women are invited every
5 years in the year they turn 30, 35,…, 60 years, these age
categories reflect different screening rounds. The cervical
cancer screening program is organized by five different
screening organizations, each accounting for a geographi-
cal region (i.e., screen region) (north, southwest, middle
west, south, and east). Screen regions were coded corre-
sponding with the place of residence at the time of the
primary smear. Socioeconomic status (SES) was defined
(low, middle, high) according to the status score, which is
an ecological variable based on the four-digit postal code
of the woman’s place of residence at the time of the pri-
mary test [25]. Status scores per four-digit postal code were
provided by the Netherlands Institute for Social Research,
www.scp.nl based on (1) mean income, (2) percentage of
households with a low income, (3) percentage of house-
holds with, on average, a low education, and (4) unem-
ployment rate in 2010. These variables were merged into
one score (i.e., status score) by a principal component
analysis. Low SES corresponded with a status score lower
than -1 (i.e., average status score minus standard devia-
tion), intermediate SES with a score of C-1 and B1, and
high SES with a score higher than 1 (i.e., average status
score plus standard deviation).
In PALGA, the type of cytology testing is not routinely
registered. Therefore, the date of conversion was retrieved
from the laboratories fixed to one of the quarters per year,
since most laboratories had a phase-in–phase-out transition
period of 2–4 months. This information was linked to
PALGA as a proxy for which type of primary cytology test
was used (i.e., in the Netherlands, laboratories supply the
tools for cytology and thus determine the type of cytology
test that is used by the general practitioner).
Type of cytology testing
With conventional cytology, cervical specimen is collected
(i.e., no data were available on the type of device or brush
used), and cells are directly smeared from the sampling
device on the slide. With SurePath, cervical specimen is
collected using a broom-like device with detachable head.
The detachable head is placed in a vial with an ethanol-
based preservative fluid. At the laboratory, the fluid and
cells are centrifuged to isolate the cells from the fluid. The
cells are resuspended in a sucrose density gradient fol-
lowed by slide transfer using gravity for adherence. With
ThinPrep, cervical specimen is collected using a Cervix
Brush, and the brush is rinsed in a vial with a methanol-
based preservative fluid. Cells are released by pushing the
brush to the bottom, forcing the bristles apart, and swirling
the brush into the fluid. Subsequently, the brush is dis-
carded. At the laboratory, cells are isolated from the fluid
by vacuum filtration and are transferred to the slide using
air pressure for adherence [26].
Statistical analyses
Since LBC was implemented per laboratory at different
points in time, calendar time is expected to differ between
the three types of cytology tests. The demographic char-
acteristics of attending women (i.e., age, screen region, and
SES) also differ between laboratories; hence, we expected
that they also differ between the cytology tests. As age,
SES, screen region, and calendar time are all associated
with CIN and/or cervical cancer [27, 28], they are all
potential confounding factors. We used a Pearson’s Chi-
squared test to assess whether their distributions differed
between the types of cytological tests. Thus, we tested
whether they were confounders or not. A p value of less
than 0.05 was considered to be statistically significant.
We performed logistic regression analyses to examine
whether CIN and cervical cancer detection rates differed
between the types of cytological tests, adjusted for con-
founding factors. Moreover, we assessed how these overall
changes in CIN and cervical cancer detection rates, if
present, were composed. First, we examined whether the
rate of primary smears classified as borderline/mildly
dyskaryotic (BMD) differed between the types of cyto-
logical tests. Second, we assessed whether CIN and cer-
vical cancer detection rates in women with a BMD smear
were different between the types of tests, which would
indicate that the positive predictive value (PPV) of a pri-
mary BMD smear differed. Third, we combined these two
steps to examine whether the tests differed in the fraction
of primary smears both classified as BMD and resulting in
the detection of a CIN or cervical cancer. By performing
the same analyses for having a[BMD smear, we could
assess whether potential differences in CIN and cervical
cancer rates were (mainly) caused by differences in the
triage (i.e., those with a primary BMD smear) or direct
referral pathway (i.e., those with a primary[BMD smear).
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Finally, we assessed the overall difference in CIN and
cervical cancer detection rates, regardless of the cytologi-
cal result.
Missing values were imputed with 10 multiple imputa-
tions for confounding factors. The odds ratio (OR) was
interpreted as relative risk if the prevalence of the outcome
(i.e., BMD,[BMD, CIN I, CIN II, CIN III, cervical cancer,
or CIN II?) was\10 % in the respective logistic regression
model analysis [29]. The software program SPSS (version
20) was used to perform the statistical analyses.
Results
We included 3,118,685 primary conventional cytology
smears, 1,313,731 primary SurePath smears, and 1,584,587
primary ThinPrep smears in our analyses. The distribution
of calendar time significantly differed between the methods
of cytology testing (p\ 0.001). In 2000, 94 % of the pri-
mary cytology tests performed within the Dutch screening
program consisted of conventional cytology, while in 2011
this percentage has dropped to 2 % (Fig. 2). The distribu-
tion of age, SES, and screen region also significantly dif-
fered between the methods of cytology testing (Table 1).
For instance, most conventional cytology tests were per-
formed in screen region 4 (28 %), while most SurePath and
ThinPrep tests were performed in screen regions 1
(38.4 %) and 2 (34.0 %), respectively. Thus, calendar time,
age, SES, and screen region were all considered con-
founding factors and missing values were imputed for
1.6 % of the primary smears.
The effect of SurePath versus conventional cytology,
adjusted for confounding factors
When comparing using SurePath with using conventional
cytology as primary test method, 4 % fewer primary
smears were classified as BMD [OR of 0.96 (95% confi-
dence interval (CI) 0.94–0.97)], while a BMD smear more
often led to a CIN I [OR of 1.26 (95% CI 1.18–1.34)] or
CIN II diagnosis [OR of 1.16 (95% CI 1.08–1.25)]. Com-
bined this led to a 20 % [OR of 1.20 (95% CI 1.13–1.27)]
and 14 % [OR of 1.14 (95% CI 1.07–1.22)] increase in the
fraction of primary smears both classified as BMD and
resulting in the detection of a CIN I or CIN II lesion
(Table 2, see for the unadjusted results the Appendix).
The rate of primary smears classified as [BMD
increased by 12 % [OR of 1.12 (95% CI 1.09–1.16)],
whereas a smear classified as [BMD led to a similar
number of CIN I, CIN II, CIN III, and cervical cancer
diagnoses. As a result, the fraction of primary smears both
classified as[BMD and resulting in the detection of a CIN
II or CIN III lesion increased by 17 % [OR of 1.17 (95% CI
1.09–1.27)] and 10 % [OR of 1.10 (95% CI 1.06–1.15)].
Overall, CIN I, CIN II, and CIN III detection rates
increased by 14 % [OR of 1.14 (95% CI 1.08–1.20)], 14 %
[OR of 1.14 (95%CI 1.09–1.20)], and 6 % [OR of 1.06 (95%
CI 1.02–1.10)], respectively, when using SurePath as com-
pared to using conventional cytology as primary testmethod.
Cervical cancer detection rates were equivocal between both
tests [OR of 0.99 (95% CI 0.86–1.14)]. CIN II? detection
rates increased by 8 % [OR of 1.08 (95% CI 1.05–1.12)].
The effect of ThinPrep versus conventional cytology,
adjusted for confounding factors
When using ThinPrep as compared to using conventional
cytology as primary test method, the rate of primary smears
classified as BMD increased by 2 % [OR of 1.02 (95% CI
1.01–1.04)], although a primary smear classified as BMD
less often resulted in a CIN III [OR of 0.87 (95% CI
0.81–0.94) or cervical cancer diagnosis [OR of 0.62 (95%CI
0.41–0.92)]. Combined this led to a marginally significant 8
% increase [OR of 1.08 (95% CI 1.00–1.15)] in the fraction
of primary smears both classified as BMD and resulting in
the detection of a CIN II lesion. The fraction of primary
smears both classified as BMD and resulting in the detection
of a CIN I lesion nonsignificantly increased [OR of 1.06
(95% CI 0.99–1.12)], while the fraction both classified as
BMD and resulting in the detection of a CIN III or cervical
cancer nonsignificantly decreased [ORs of 0.93 (95% CI
0.87–1.00) and 0.66 (95% CI 0.43–1.00) respectively]
(Table 2, see for the unadjusted results the Appendix).
The rate of primary smears classified as [BMD
decreased with 4 % [OR of 0.96 (95% CI 0.93–0.99)]. A
Fig. 2 Distribution of the types of cytological tests used within the
Dutch screening program. The total number of primary smears where
the type of cytological test was known varied from 441,663 in 2000 to
541,587 in 2007
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primary smear classified as[BMD less often resulted in a
CIN I diagnosis [OR of 0.86 (95% CI 0.77–0.97)], although
it nonsignificantly resulted in more CIN II and CIN III
diagnoses [ORs of 1.08 (95% CI 0.99–1.17) and 1.06 (95%
CI 0.99–1.13) respectively]. As a result, the fraction of
primary smears both classified as[BMD and resulting in
the detection of a CIN I lesion decreased by 17 % (OR of
0.83 [95% CI 0.74–0.92)].
In total, using ThinPrep as primary test method did not
have a significant effect on CIN I (OR of 0.98 (95% CI
0.93–1.04)], CIN II [OR of 1.04 (95% CI 0.99–1.10)], CIN
III [OR of 0.98 (95% CI 0.94–1.01)] (Table 2), or CIN II?
detection rates [OR of 0.99 (95% CI 0.96–1.02)]. Cervical
cancer detection rates were nonsignificantly lower [OR of
0.87 (95% CI 0.75–1.01)].
Discussion
Using SurePath versus conventional cytology as primary
test method resulted in a 12 % increase in the rate of pri-
mary smears classified as [BMD. The rate of primary
smears classified as BMD decreased by 4 % and women
with a primary BMD smear were more often diagnosed
with CIN I or II. Combined this led to increased fractions
of primary smears both classified as BMD and resulting in
the detection of a CIN I or CIN II lesion and to increased
fractions of primary smears both classified as[BMD and
resulting in the detection of a CIN II or CIN III lesion
detected. Altogether, the detection of CIN II? increased by
8 % accompanied by a 14 % increase in the detection of
CIN I. Cervical cancer rates were unaffected. The com-
parison of using ThinPrep versus conventional cytology did
not result in such findings, although the sensitivity to detect
cervical cancers might be lower.
Given the differences in preparation between both LBC
methods, it is possible that the sensitivity for CIN II?
differs between them as well. For instance, it was shown
that the cell yield is larger when the collecting device was
retained instead of discarded from the vial with preserva-
tive fluid [30, 31], meaning that if the protocol is followed,
the cell yield is larger when using SurePath (i.e., collecting
device is retained) than when using ThinPrep (i.e., col-
lecting device is discarded). Therefore, the probability of
transferring abnormal cells from the cervical specimen (if
present) to the slide is probably larger when using Sur-
ePath. The study of Rask et al. [16] seems to confirm this,
since they found that replacing conventional cytology by
SurePath resulted in a significant 31 % increase in cyto-
logical abnormalities within 23–29 aged women, while
replacing conventional cytology by ThinPrep resulted in a
nonsignificant 11 % decrease [16].
Table 1 Population
characteristics
Conventional SurePath ThinPrep p value
N 3,118,685 1,313,731 1,584,587
Screen region \0.001
1, n (%) 430,548 (13.8) 503,967 (38.4) 352,790 (22.3)
2, n (%) 822,189 (26.4) 178,844 (13.6) 538,890 (34.0)
3, n (%) 482,137 (15.5) 311,276 (23.7) 296,609 (18.7)
4, n (%) 872,931 (28.0) 294,939 (22.5) 206,098 (13.0)
5, n (%) 501,852 (16.1) 24,471 (1.9) 187,279 (11.8)
Unknown, n (%) 9,028 (0.3) 234 (0.0) 2,921 (0.2)
SES \0.001
Low, n (%) 257,544 (8.3) 156,058 (11.9) 107,983 (6.8)
Middle, n (%) 2,574,027 (82.5) 1,045,158 (79.6) 1,331,613 (84.0)
High, n (%) 239,623 (7.7) 87,591 (6.7) 132,439 (8.4)
Unknown, n (%) 47,491 (1.5) 24,924 (1.9) 12,552 (0.8)
Age \0.001
29–33 years, n (%) 428,600 (13.7) 170,699 (13.0) 195,935 (12.4)
34–38 years, n (%) 522,173 (16.7) 191,193 (14.6) 220,462 (13.9)
39–43 years, n (%) 533,438 (17.1) 222,906 (17.0) 271,924 (17.2)
44–48 years, n (%) 496,856 (15.9) 219,118 (16.7) 265,672 (16.8)
49–53 years, n (%) 446,596 (14.3) 195,127 (14.9) 243,354 (15.4)
54–58 years, n (%) 388,637 (12.5) 171,194 (13.0) 207,405 (13.1)
59–63 years, n (%) 302,385 (9.7) 143,494 (10.9) 179,835 (11.3)
The distributions of factors associated with CIN detection rates between the three primary test methods are
given. If a distribution differs significantly between the primary tests (which is tested with a Pearson’s Chi-
square test), the variable is considered to be a confounding factor
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Our research demonstrated that CIN II? detection rates are
similar between ThinPrep and conventional cytology, which
is compatible with results of previous studies. For instance, the
observed CIN II? detection rate ratio of 0.99 (95% CI
0.96–1.02) fits with the pooled relative CIN II? sensitivity of
1.03 (0.97–1.09) as reported in the meta-analysis of Arbyn
et al. (i.e., our point estimate lies within the 95% CI) [18].
However, that ratio was based on seven studies comparing
LBC with conventional cytology of which two did not use
ThinPrep as LBC test method. When only focusing on the
included ThinPrep studies, we found and calculated (i.e.,
using data provided in the study) CIN II? detection rate ratios
of 1.17 (95% CI 0.87–1.56) [22], 0.97 (95% CI 0.61–1.55)
[20], 0.95 (95% CI 0.62–1.48) [5], and 1.09 (95% CI
Table 2 Logistic regression
analyses on the classification of
smears and histological
outcomes when tested by
SurePath or Thinprep versus
conventional cytology, adjusted
for age, SES, screen region, and
calendar time
Outcome SurePath ThinPrep
BMDa 0.96 (0.94–0.97) 1.02 (1.01–1.04)
PPV of a primary BMD smear on histological outcomesb
CIN I 1.26 (1.18–1.34) 1.03 (0.97–1.10)
CIN II 1.16 (1.08–1.25) 1.04 (0.97–1.12)
CIN III 0.95 (0.88–1.02) 0.87 (0.81–0.94)
Cervical cancer 0.74 (0.49–1.12) 0.62 (0.41–0.92)
Fraction of primary smears both classified as BMD and resulting in the detection of the following
histological outcomesc
CIN Ia 1.20 (1.13–1.27) 1.06 (0.99–1.12)
CIN IIa 1.14 (1.07–1.22) 1.08 (1.00–1.15)
CIN IIIa 0.99 (0.92–1.06) 0.93 (0.87–1.00)
Cervical Cancera 0.77 (0.51–1.15) 0.66 (0.43–1.00)
[BMDa 1.12 (1.09–1.16) 0.96 (0.93–0.99)
PPV of a primary[BMD smear on histological outcomesb
CIN I 0.92 (0.83–1.03) 0.86 (0.77–0.97)
CIN II 1.06 (0.98–1.15) 1.08 (0.99–1.17)
CIN III 0.97 (0.91–1.03) 1.06 (0.99–1.13)
Cervical cancer 0.94 (0.80–1.10) 0.98 (0.83–1.15)
Fraction of primary smears both classified as[BMD and resulting in the detection of the following
histological outcomesd
CIN Ia 1.05 (0.94–1.16) 0.83 (0.74–0.92)
CIN IIa 1.17 (1.09–1.27) 1.02 (0.94–1.10)
CIN IIIa 1.10 (1.06–1.15) 1.00 (0.96–1.04)
Cervical cancera 1.07 (0.91–1.24) 0.93 (0.79–1.09)
Overall histological outcomes
CIN Ia 1.14 (1.08–1.20) 0.98 (0.93–1.04)
CIN IIa 1.14 (1.09–1.20) 1.04 (0.99–1.10)
CIN IIIa 1.06 (1.02–1.10) 0.98 (0.94–1.01)
Cervical cancera 0.99 (0.86–1.14) 0.87 (0.75–1.01)
Odds ratios with a 95% confidence interval are given. This table shows how the overall changes in CIN and
cervical cancer detection rates, if present, are composed. The differences in the odds of primary smears
classified as BMD combined with the differences in the odds of the PPV of a BMD smear led to differences
in the fraction of primary smears both classified as BMD and resulting in the detection of a CIN or cervical
cancer. By performing the same analyses for having a[BMD smear, we could assess whether potential
differences in CIN and cervical cancer rates were (mainly) caused by differences in the triage (i.e., those
with a primary BMD smear) or direct referral pathway (i.e., those with a primary[BMD smear). Alto-
gether, this led to differences in odds of overall CIN and cervical cancer detection
Underlined = significant. A p value of\0.05 was considered to be statistically significant
BMD borderline/mildly dyskaryotic, PPV positive predictive value
a Odds ratio could be interpreted as detection rate ratio because the prevalence of the outcome was\10 %
b This can be interpreted as: Does a BMD or[BMD smear more often lead to the following histological
outcomes when using SurePath or ThinPrep as compared to conventional cytology
c Histological outcomes detected via triage
d Histological outcomes detected via direct colposcopy
20 Cancer Causes Control (2016) 27:15–25
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0.80–1.48) [21], which were all compatible to the detection
rates as observed in the present study. The CIN II? detection
rate ratio of the fifth includedThinPrep studywas not provided
nor could be calculated [11]. Furthermore, the largest ran-
domized controlled trial performed so far, including almost
90,000 participants, found a CIN II? detection rate ratio of
1.00 (95% CI 0.84–1.20) [2] which also fits our data. When
focusing on studies comparing SurePath with conventional
cytology, only one previous study matched our criteria (i.e.,
providing a CIN II? detection rate ratio, or data needed to
calculate it, at a cutoff of ASCUS or BMD) [23]. Again, their
data [i.e., a CIN II? detection rate of 1.01 (95%CI 0.76–1.33)]
fitted with ours [i.e., a ratio of 1.08 (95% CI 1.05–1.12)] (i.e.,
our point estimate lies within the reported 95% CI).
It is expected that from 2016 onwards, primary cytology
screening will be replaced by primary HPV screening in the
Dutch cervical cancer screening program. If high-risk HPV is
present, a reflex cytology triage test will be carried out on the
same sample followed by another triage test 6 months later, if
the reflex cytology triage test shows no abnormalities. If one
of these smears is classified as CBMD, the woman will be
referred to the gynecologist for colposcopy, otherwise she
will be referred to routine screening. Whether our results can
be extended from a primary screening to a triage population
depends on the performance of the cytology tests on (a) fluid
remnant after primary HPV testing in HPV-positive women
(in case of reflex triage testing) and (b) directly taken material
in (previously) HPV-positive women (in case of triage testing
at 6 months). Although prior knowledge of the HPV status
influences the interpretation of cytological smears [32, 33],
we assume this effect to be similar for the three types of
cytology tests. If true, we expect the differences in sensitivity
between Surepath, ThinPrep, and conventional cytology in a
triage population to be equivalent to the differences in a
primary screening population. However, this assumption has
not been tested yet. In addition, because conventional cytol-
ogy cannot be performed on fluid remnant after primary HPV
testing [3, 18], our results of comparing SurePath and Thin-
Prep with conventional cytology cannot be extended to reflex
triage testing. As data of Cuzick et al. [34] suggested that the
performance of HPV assays depends on the type of LBC test
used, it is also possible that the performance of LBC tests on
fluid remaining after HPV testing depends on the type ofHPV
assay used. Thus, more research is needed to assess which
combination of primary HPV test and secondary reflex LBC
test has the highest CIN II? sensitivity.
We were the first who compared CIN and cervical cancer
detection rates between Surepath, ThinPrep, and conven-
tional cytology. Furthermore, we included more than
6 million primary smears, and we showed its effect in real
practice instead of in a strictly controlled setting.
At the same time, the lack of a more controlled setting is
one of the limitations of our study. As ThinPrep and SurePath
were used in different women, differences in demographic
factors were inevitable. Although we were able to correct for
the confounders age, screen region, SES, and calendar time,
we were not able to correct for other potential confounding
factors such as screening history or compliance with the
given advice. Both could have resulted in biased effect
estimates if their distribution differed between the types of
cytology tests. In addition, no data are present on whether
cytology triage testing at 6 months was combined with HPV
testing. Because of the possibility of co-testing, it is likely
that the use of HPV triage is correlated with the use of pri-
mary LBC testing. As it is known that more CIN I and CIN II
lesions are detected when cytology triage is combined with
HPV [35], it is probable that the increased sensitivity of
SurePath to detect CIN I and CIN II was partly caused by the
simultaneous use of HPV testing. However, the entire
increase in CIN III detection rates when comparing Surepath
with conventional cytology, and for a large part also the
increase in CIN II detection rates, is caused by an increase in
primary smears being classified as[BMD. Therefore, we
still believe that SurePath results in increased CIN II?
detection rates, although it might be accompanied by a
smaller increase in CIN I detection than estimated. Also, we
did not have individual data on which type of primary test
was used. Therefore, we combined the date of the primary
smear and the quarter of the year within which the laboratory
introduced the LBC test as proxy for the type of cytology test
that was used. This means that primary screening smears
taken during this quarter could have been misclassified,
resulting in slightly underestimated effects. Another short-
coming of the study was that we were not able to correct for
the use of automated reading, although this has only been
introduced in relatively few Dutch laboratories. As study
results on the effect of automated screening are heteroge-
neous, it is unknown how this affected our effect estimates. If
automated reading does not affect the sensitivity for CIN II?,
as shown byKlug and Palmer et al. [36, 37], our estimates are
not biased. If automated reading results in a decreased sen-
sitivity for CIN II?, as shown in the MAVARIC study [38],
we might have underestimated the effect of using SurePath
and ThinPrep on CIN II? detection rates. If it results in an
increased sensitivity, we might have overestimated the
effects. At last, we did not correct for possible learning curve
effects, since the aim of our study was to examine the effect
of using SurePath and ThinPrep in routine practice, which
also includes a possible learning effect.
Our results indicate that the widespread use of SurePath
as primary test method has led to an increased probability
to detect both CIN I and CIN II? lesions. As only a small
fraction of CIN I lesions progress to cancer, increased CIN
I detection is often regarded as increased overdiagnosis. In
contrast, CIN II? lesions are associated with a substantial
cancer risk and are therefore often considered as clinically
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relevant. However, whether the increased probability to
detect CIN II? lesions indeed corresponds with an
increased sensitivity for progressive lesions remains to be
investigated. If this is the case, using SurePath would in
due time result in a decrease in the incidence and mortality
of cervical cancer, thereby increasing the health benefits of
the screening program. If not, it would only lead to
increased burden and harms through overdiagnosis (and
treatment) of regressive CIN lesions. The widespread use
of ThinPrep as primary test method did not lead to changes
in CIN II? detection rates, although cervical cancer
detection was nonsignificantly lower. Whether these results
imply a decreased sensitivity for progressive CIN II?
lesions is unknown. For evidence as to whether the
detection of progressive CIN II? lesions is higher with any
of the LBC systems than with conventional cytology,
cervical interval carcinoma rates have to be compared.
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Appendix
See Table 3.
Table 3 Logistic regression analyses on the classification of smears and histological outcomes when tested by SurePath or Thinprep versus
conventional cytology, unadjusted and adjusted for confounding factors
Effect of using either SurePath or ThinPrep instead of conventional cytology as primary test method
Unadjusted Adjusted
for year
Adjusted for
year and age
Adjusted for year,
age, and screen region
Adjusted for year, age,
screen region, and SES
Fraction of primary smears classified as BMD
SurePath 1.23 (1.21–1.24) 0.99 (0.97–1.01) 0.99 (0.97–1.00) 0.97 (0.95–0.98) 0.96 (0.94–0.97)
ThinPrep 1.40 (1.39–1.42) 1.05 (1.03–1.07) 1.05 (1.03–1.06) 1.02 (1.00–1.04) 1.02 (1.01–1.04)
PPV of a primary BMD smear on histological outcomesa
CIN I
SurePath 1.37 (1.30–1.43) 1.23 (1.17–1.31) 1.23 (1.16–1.30) 1.26 (1.19–1.34) 1.26 (1.18–1.34)
ThinPrep 1.16 (1.11–1.21) 1.03 (0.97–1.09) 1.02 (0.96–1.08) 1.04 (0.97–1.10) 1.03 (0.97–1.10)
CIN II
SurePath 1.29 (1.22–1.36) 1.17 (1.10–1.25) 1.15 (1.07–1.23) 1.17 (1.09–1.26) 1.16 (1.08–1.25)
ThinPrep 1.18 (1.12–1.24) 1.07 (0.99–1.14) 1.04 (0.97–1.12) 1.04 (0.97–1.12) 1.04 (0.97–1.12)
CIN III
SurePath 0.94 (0.89–1.00) 0.99 (0.92–1.06) 0.95 (0.89–1.02) 0.94 (0.88–1.02) 0.95 (0.88–1.02)
ThinPrep 0.87 (0.82–0.92) 0.93 (0.87–1.00) 0.91 (0.84–0.98) 0.87 (0.81–0.94) 0.87 (0.81–0.94)
Cervical cancer
SurePath 0.70 (0.51–0.95) 0.76 (0.52–1.11) 0.76 (0.53–1.11) 0.74 (0.60–0.91) 0.74 (0.49–1.12)
ThinPrep 0.58 (0.43–0.77) 0.65 (0.43–0.96) 0.64 (0.43–0.96) 0.62 (0.50–0.77) 0.62 (0.41–0.92)
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Table 3 continued
Effect of using either SurePath or ThinPrep instead of conventional cytology as primary test method
Unadjusted Adjusted
for year
Adjusted for
year and age
Adjusted for year,
age, and screen region
Adjusted for year, age,
screen region, and SES
Fraction of primary smears both classified as BMD and resulting in the detection of the following histological outcomesb
CIN I
SurePath 1.62 (1.55–1.69) 1.20 (1.14–1.27) 1.20 (1.14–1.27) 1.22 (1.15–1.29) 1.20 (1.13–1.27)
ThinPrep 1.60 (1.53–1.67) 1.07 (1.01–1.13) 1.07 (1.01–1.14) 1.05 (0.99–1.12) 1.06 (0.99–1.12)
CIN II
SurePath 1.55 (1.47–1.64) 1.15 (1.08–1.22) 1.15 (1.08–1.22) 1.16 (1.09–1.24) 1.14 (1.07–1.22)
ThinPrep 1.63 (1.55–1.71) 1.11 (1.04–1.18) 1.11 (1.04–1.19) 1.07 (1.00–1.15) 1.08 (1.00–1.15)
CIN III
SurePath 1.16 (1.10–1.22) 0.97 (0.91–1.04) 0.98 (0.92–1.05) 0.99 (0.93–1.07) 0.99 (0.92–1.06)
ThinPrep 1.22 (1.16–1.28) 0.98 (0.91–1.05) 0.99 (0.92–1.06) 0.93 (0.87–1.00) 0.93 (0.87–1.00)
Cervical cancer
SurePath 0.85 (0.63–1.16) 0.75 (0.52–1.09) 0.75 (0.52–1.09) 0.77 (0.63–0.95) 0.77 (0.51–1.15)
ThinPrep 0.81 (0.60–1.08) 0.68 (0.46–1.01) 0.68 (0.46–1.01) 0.66 (0.53–0.81) 0.66 (0.43–1.00)
Fraction of primary smears classified as[BMD
SurePath 1.21 (1.18–1.24) 1.06 (1.03–1.09) 1.07 (1.04–1.10) 1.15 (1.11–1.18) 1.12 (1.09–1.16)
ThinPrep 1.11 (1.09–1.14) 0.93 (0.90–0.96) 0.93 (0.90–0.96) 0.95 (0.92–0.99) 0.96 (0.93–0.99)
PPV of a primary[BMD smear on histological outcomesa
CIN I
SurePath 1.03 (0.95–1.12) 0.94 (0.85–1.05) 0.93 (0.84–1.04) 0.92 (0.83–1.03) 0.92 (0.83–1.03)
ThinPrep 0.98 (0.90–1.06) 0.87 (0.77–0.97) 0.87 (0.78–0.98) 0.86 (0.77–0.97) 0.86 (0.77–0.97)
CIN II
SurePath 1.14 (1.07–1.21) 1.04 (0.96–1.12) 1.04 (0.97–1.13) 1.06 (0.98–1.15) 1.06 (0.98–1.15)
ThinPrep 1.23 (1.16–1.30) 1.09 (1.00–1.18) 1.08 (1.00–1.17) 1.08 (0.99–1.18) 1.08 (0.99–1.17)
CIN III
SurePath 0.99 (0.94–1.03) 0.97 (0.92–1.03) 0.99 (0.94–1.05) 0.97 (0.91–1.03) 0.97 (0.91–1.03)
ThinPrep 1.13 (1.08–1.19) 1.12 (1.05–1.19) 1.09 (1.03–1.17) 1.06 (0.99–1.13) 1.06 (0.99–1.13)
Cervical cancer
SurePath 0.96 (0.85–1.08) 0.99 (0.86–1.15) 0.98 (0.85–1.13) 0.93 (0.80–1.09) 0.94 (0.80–1.10)
ThinPrep 0.95 (0.84–1.06) 0.99 (0.85–1.16) 1.00 (0.85–1.17) 0.98 (0.83–1.15) 0.98 (0.83–1.15)
Fraction of primary smears both classified as[BMD and resulting in the detection of the following histological outcomesc
CIN I
SurePath 1.25 (1.15–1.35) 1.01 (0.91–1.11) 1.01 (0.91. 1.11) 1.07 (0.96–1.19) 1.05 (0.94–1.16)
ThinPrep 1.09 (1.01–1.18) 0.81 (0.73–0.90) 0.82 (0.73–0.91) 0.82 (0.74–0.92) 0.83 (0.74–0.92)
CIN II
SurePath 1.35 (1.27–1.43) 1.10 (1.02–1.18) 1.10 (1.02–1.18) 1.20 (1.11–1.29) 1.17 (1.09–1.27)
ThinPrep 1.32 (1.25–1.39) 0.99 (0.92–1.07) 1.00 (0.93–1.08) 1.02 (0.94–1.10) 1.02 (0.94–1.10)
CIN III
SurePath 1.20 (1.16–1.24) 1.05 (1.01–1.09) 1.05 (1.01–1.09) 1.12 (1.08–1.17) 1.10 (1.06–1.15)
ThinPrep 1.17 (1.14–1.21) 0.97 (0.93–1.01) 0.98 (0.94–1.02) 1.00 (0.95–1.04) 1.00 (0.96–1.04)
Cervical cancer
SurePath 1.16 (1.03–1.31) 1.05 (0.91–1.21) 1.05 (0.91–1.21) 1.08 (0.93–1.26) 1.07 (0.91–1.24)
ThinPrep 1.05 (0.94–1.18) 0.92 (0.79–1.08) 0.92 (0.79–1.07) 0.93 (0.79–1.09) 0.93 (0.79–1.09)
Overall histological outcomes
CIN I
SurePath 1.50 (1.45–1.56) 1.13 (1.08–1.19) 1.13 (1.08–1.19) 1.16 (1.10–1.21) 1.14 (1.08–1.20)
ThinPrep 1.46 (1.40–1.51) 0.99 (0.94–1.04) 0.99 (0.95–1.05) 0.98 (0.93–1.03) 0.98 (0.93–1.04)
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